(RS)-2-(2-bromoethyl)-3-hydroxyisoindolinone | 97694-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (RS)-2-(2-bromoethyl)-3-hydroxyisoindolinone
• 英文别名: N-(2-Bromoethyl)phthalimidine；3-Hydroxy-2-(2-bromoethyl)-1-oxoisoindolin；2-(2-bromoethyl)-3-hydroxy-3H-isoindol-1-one
• CAS: 97694-82-1
• 化学式: C₁₀H₁₀BrNO₂
• 分子量: 256.099
• InChiKey: HCWDWHMUDFVKKL-UHFFFAOYSA-N

物化性质

• 熔点：
  129-132 °C(Solv: chloroform (67-66-3); ethyl ether (60-29-7))
• 沸点：
  407.0±45.0 °C(Predicted)
• 密度：
  1.664±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (RS)-2-(2-bromoethyl)-3-hydroxyisoindolinone 在 氢氧化钾 、 potassium tert-butylate 作用下， 以 水 、 叔丁醇 为溶剂， 反应 5.0h， 生成 邻羧基苯甲醛
  参考文献：
  名称：

  Wharton, Clifford J.; Wrigglesworth, Roger, Journal of the Chemical Society. Perkin transactions I, 1985, p. 809 - 814

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(2-溴乙基)邻苯二甲酰亚胺 生成 (RS)-2-(2-bromoethyl)-3-hydroxyisoindolinone
  参考文献：
  名称：

  Isoindoles having cardiovascular activity

  摘要：

  式(I)的异吲哚化合物 ##STR1## 其中R.sub.1代表氢; C.sub.1-C.sub.6烷基; 可选用卤素，羟基，C.sub.1-C.sub.6烷氧基，亚甲二氧基取代的苯甲基; C.sub.2-C.sub.8脂肪酰基; 可选用卤素，羟基，C.sub.1-C.sub.6烷氧基，C.sub.2-C.sub.6烷酰基，C.sub.2-C.sub.6烷酰氧基，C.sub.1-C.sub.4烷基，三氟甲基，亚甲二氧基取代的苯甲酰基; R.sub.2-R.sub.3独立选择自氢; 卤素; C.sub.1-C.sub.4烷基; 三氟甲基; 羟基; 硝基; 氨基; 单或双C.sub.1-C.sub.4烷基氨基; 氰基; C.sub.1-C.sub.6烷氧基; C.sub.2-C.sub.6烷氧羰基; Y为乙烯或含有3至6个碳原子的直链或支链烷基链，以及其在药学上可接受的酸盐。这些化合物具有抗心绞痛活性，并用于制备抗心绞痛治疗药物。

  公开号：

  US05376673A1

文献信息

• Heterocyclic derivatives, their preparation and medicinal products
  申请人：Rhone-Poulenc Sante

  公开号：US05114949A1

  公开（公告）日：1992-05-19

  Compounds are disclosed of formula: R.sub.1 --(CH.sub.2).sub.n --Het in which R.sub.1 represents a residue of formula ##STR1## X represents a hydrogen atom or an alkyl radical, Y represents a hydrogen atom or an alkyl or alkoxy radical, Z represents an alkyl radical, n is equal to 2 or 3, Het represents a substituted piperidino (substituted at the 4-position with a 1-indenylidene, 1-indenyl or 1-indanyl radical or with a chain --(CH.sub.2).sub.m --R.sub.2 or .dbd.CH--R.sub.2), substituted 1,2,3,6-tetrahydro-1-pyridyl (substituted at the 4-position with a chain --(CH.sub.2).sub.m --R.sub.2), m is equal to 1 or 2, and R.sub.2 represents an optionally substituted 2- or 3-indolyl radical, a 1- or 2-indanyl, 1- or 2-indenyl, an optionally substituted 1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-2-yl radical, a 1,2,3,4-tetrahydro-3-quinolyl radical, an optionally substituted 1,2,3,4-tetrahydro-2-naphthyl radical or a 1-indolyl radical, their preparation and medicinal products containing them.

  揭示了具有以下结构的化合物：R.sub.1--(CH.sub.2).sub.n--Het，其中R.sub.1代表以下结构的残基##STR1##X代表氢原子或烷基基团，Y代表氢原子或烷基或烷氧基团，Z代表烷基基团，n等于2或3，Het代表取代的哌啶基（在4位取代有1-茚基亚甲基、1-茚基或1-茚基基团或具有链--(CH.sub.2).sub.m--R.sub.2或.dbd.CH--R.sub.2)，取代的1,2,3,6-四氢-1-吡啶基（在4位取代有链--(CH.sub.2).sub.m--R.sub.2），m等于1或2，R.sub.2代表可选取代的2-或3-吲哚基团，1-或2-茚基、1-或2-茚基、可选取代的1,2,3,4-四氢-5H-吡啶并[4,3-b]吲哚-2-基团、1,2,3,4-四氢-3-喹啉基团、可选取代的1,2,3,4-四氢-2-萘基团或1-吲哚基团，它们的制备以及含有它们的药物产品。
• COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
  申请人：Yeung Kap-Sun

  公开号：US20120201783A1

  公开（公告）日：2012-08-09

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

  该披露提供了I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物对丙型肝炎病毒（HCV）具有活性，并可能用于治疗感染HCV的人。
• COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：Ardelyx, Inc.

  公开号：EP3939964A1

  公开（公告）日：2022-01-19

  The present disclosure is directed to a pharmaceutical composition comprising a compound of formula (X), in combination with another active agent, and to the use of said composition in methods for the treatment of disorders associated with fluid retention or salt overload or gastrointestinal tract disorders, such as irritable bowel syndrome and constipation associated with cystic fibrosis. The methods generally comprise administering to a mammal in need thereof a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto.

  本公开涉及一种药物组合物，该组合物包含与另一种活性剂组合的式(X)化合物，并涉及将所述组合物用于治疗与体液潴留或盐超载相关的疾病或胃肠道疾病（如肠易激综合征和与囊性纤维化相关的便秘）的方法。这些方法一般包括向有需要的哺乳动物施用包含此类化合物的药物组合物，该组合物设计为在胃肠道（GI）中基本活跃，以抑制其中钠离子和氢离子的 NHE 介导的反转运。更具体地说，该方法包括向有需要的哺乳动物施用包含这种化合物的药物组合物，该化合物可抑制胃肠道中NHE-3、-2和/或-8介导的钠离子和/或氢离子的反转运，并且设计成基本上不渗透到上皮细胞层，或更具体地说，不渗透到胃肠道上皮细胞层。由于该化合物基本上不渗透，因此不会被吸收，从而基本上不会被全身生物利用，从而限制了其他内脏器官（如肝脏、心脏、大脑等）对该化合物的接触。
• WHARTON, C. J.;WRIGGLESWORTH, R., J. CHEM. SOC. PERKIN TRANS., 1985, N 4, 809-813
  作者：WHARTON, C. J.、WRIGGLESWORTH, R.

  DOI：——

  日期：——
• ISOINDOLES HAVING CARDIOVASCULAR ACTIVITY
  申请人：ITALFARMACO S.p.A.

  公开号：EP0576475B1

  公开（公告）日：1995-09-20